A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 1, 2002, Pages 11-16

  Phillips, William T ^a   Medina, Luis A ^a   Klipper, Robert ^a   Goins, Beth ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; BLUE DEXTRAN; LIPOSOME; MEDRONATE TECHNETIUM TC 99M;

ABDOMEN; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RETENTION; MALE; MEDIASTINUM LYMPH NODE; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; RAT; SCINTIGRAPHY; SPLEEN;

ANIMALS; DRUG CARRIERS; LIPOSOMES; LYMPH NODES; MALE; PERITONEAL CAVITY; PHARMACEUTICAL PREPARATIONS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TECHNETIUM TC 99M EXAMETAZIME; TISSUE DISTRIBUTION;

EID: 0036785432     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.037119     Document Type: Article

References (42)

1. Alberts D, Liu P, Hannigan E, O'Toole R, Williams S, Young J, Franklin E, Clarke-Pearson D, Malviya V, and DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955.
2. Allen T, Hansen C, and Guo L (1993) Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim Biophys Acta 1150:9-16.
3. Berek J, Bertelson K, DuBois A, Brady M, Carmichael J, Eisenhauer E, Gore M, Grenman S, Hamilton T, Hansen S, et al. (1999) Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10:87-92.
4. Cho H, Lush R, Bartlett D, Alexander H, Wu P, Libutti S, Lee K, Venzon D, Bauer KSR, Reed E, and Figg W (1999) Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (chpp) to patients with peritoneal carcinomatosis. J Clin Pharmacol 39:394-401.
5. Daoud SS (1994) Combination chemotherapy of human ovarian xenografts with intraperitoneal liposome-incorporated valinomycin and cis-diamminedichloro-platinum (II). Can Chem Pharm 33:307-312.
6. De Bree E, Witkamp AJ, and Zoetmulder FAN (2002) Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol 79:46-61.
7. Dedrick RL, Myers CE, Bungay PM, and DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1-11.
8. Ellens H, Morselt H, and Scherphof G (1981) In vivo fate of large unilamellar sphingomyelin cholesterol liposomes after intraperitoneal and intravenous injection into rats. Biochim Biophys Acta 674:10-18.
9. Eltabbakh G, Yadav P, Morgan A, and Yadev P (1999) Clinical picture of women with early stage ovarian cancer. Gynecol Oncol 81:337.
10. Hirano K and Hunt CA (1985) Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. J Pharm Sci 74:915-921.
11. Hirnle P, Harzmann R, and Wright J (1988) Patent blue V encapsulation in liposomes: potential applicability to endolymphatic therapy and preoperative chromolymphography. Lymphology 21:187-189.
12. Howell S, Kirmani S, McClay E, Kim S, Braly P, and Plaxe S (1991) Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma. Sem Oncol 18:5-10.
13. Hribaschek A, Kuhn R, Pross M, Lippert H, Halangk W, Boltze C, and Ridwelski K (2001) Prophylaxis of peritoneal carcinomatosis in experimental investigations. Int J Colorectal Dis 16:340-345.
14. Kaye SB (2001) Future directions for the management of ovarian cancer. Eur J Cancer 37:S19-S23.
15. Kresta A, Shek P, Odumeru J, and Bohnen J (1993) Distribution of free and liposome-encapsulated cefoxitin in experimental intra-abdominal sepsis in rats. J Pharm Pharmacol 45:779-783.
16. Lasic D (1996) Liposomes. Sci Med (Phila) 3:34-43.
17. Madhavan S and Northfelt DW (1995) Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 87:1556-1557.
18. Malik STA, Martin D, Hart I, and Balkwill F (1991) Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF. Br J Cancer 63:399-403.
19. Markman M (1998) Intraperitoneal therapy of ovarian cancer. Semin Oncol 25:356-360.
20. Markman M (2001) Intraperitoneal drug delivery of antineoplastics. Drugs 61:1057-1065.
21. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JLJ, Rubin S, Curtin J, Barakat R, Phillips M, et al. (1992) Phase I trial of intraperitoneal Taxol: a gynecologic oncology group study. J Clin Oncol 10:1485-1491.
22. Meredith R, Partiridge E, Alvarez R, Khazaeli M, Plott G, Russell C, Wheeler R, Liu T, Grizzle W, Schlom J, and LoBuglio A (1996) Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-cc49. J Nucl Med 37:1491-1496.
23. Montero C, Gimferrer J, Baldo X, and Ramirez J (2000) Mediastinal metastasis of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 91:199-200.
24. Oussoren C, Zuidema J, Crommelin DJA, and Storm G (1997) Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta 1328:261-272.
25. 14C]Adriamycin following intraperitoneal administration to rats. Cancer Res 41:1311-1317.
26. 14C] cytosine b-D-arabinofuranoside following intraperitoneal administration to rats. Drug Metab Dispos 10:40-46.
27. 99mTc] human serum albumin. Nucl Med Biol 28:435-444.
28. Phillips WT, Klipper R, and Goins B (2000) Novel method of greatly enhanced delivery of liposomes to lymph nodes. J Pharmacol Exp Ther 295:309-313.
29. 99mTc-labeled liposomes encapsulating blue dye for identification of the sentinel lymph node. J Nucl Med 42:446-451.
30. Phillips WT, Rudolph AS, Goins B, Timmons JH, Klipper R, and Blumhardt R (1992) A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Nucl Med Biol 19:539-547.
31. Reimer D, Kong S, Monck M, Wyles J, Tam P, Wasan E, and Bally M (1999) Liposomal lipid and plasmid DNA delivery to B16/B16 tumors after intraperitoneal administration of cationic liposome DNA aggregates. J Pharmacol Exp Ther 2:807-815.
32. Rosa P and Clementi F (1983) Absorption and tissue distribution of doxorubicin entrapped in liposomes following intravenous or intraperitoneal administration. Pharmacology 26:221-229.
33. Sadzuka Y, Hirama R, and Sonobe T (2002) Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy. Toxicol Lett 126:83-90.
34. Sadzuka Y, Hirota S, and Sonobe T (2000) Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination. Toxicol Lett 116:51-56.
35. Schneider J (1994) Intraperitoneal chemotherapy. Obstet Gynecol Clin North Am 21:195-212.
36. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, and Bernacki RJ (1997) Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 71:103-107.
37. Sharma A, Sharma US, and Straubinger RM (1996) Paclitaxel-liposomes for intracavitary therapy of intraperitoneal p388 leukemia. Cancer Lett 107:265-272.
38. Stewart JCM (1980) Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104:10-14.
39. Vadiei K, Zahid HS, Khokhar AR, Al-Baker S, Sampedro F, and Perez-Soler R (1992) Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) and cisplatin given i.v. and i.p. in the rat. Can Chem Pharm 30:365-369.
40. Weisberger AS, Levine B, and Storaasli JP (1955) Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 159:1704-1707.
41. 125I-albumin as markers to estimate lymph drainage of the peritoneal cavity in sheep. J Appl Physiol 76:867-874.
42. Zakaria E, Simonsen O, Rippe A, and Rippe J (1996) Transport of tracer albumin from peritoneum to plasma: role of diaphragmatic, visceral and parietal lymphatics. Am J Physiol 270:H1549-H1556.